

Expert recommendations on the management of hypermetastatic cervical cancer receiving bevacizumab in the UK

British Journal of Cancer

121, 109-116

DOI: [10.1038/s41416-019-0481-y](https://doi.org/10.1038/s41416-019-0481-y)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Synthesis of a functionalized dipeptide for targeted delivery and pH-sensitive release of chemotherapeutics. <i>Chemical Communications</i> , 2020, 56, 285-288.	2.2	12
2	Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 35-45.	3.2	22
3	Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment. <i>Cancer Treatment Reviews</i> , 2020, 90, 102107.	3.4	21
4	2020 International Society of Hypertension Global Hypertension Practice Guidelines. <i>Hypertension</i> , 2020, 75, 1334-1357.	1.3	1,895
5	2020 International Society of Hypertension global hypertension practice guidelines. <i>Journal of Hypertension</i> , 2020, 38, 982-1004.	0.3	452
6	Exploiting the folate receptor $\hat{\pm}$ in oncology. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 349-359.	12.5	262
7	Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188446.	3.3	41
8	Investigation of drugs affecting hypertension in bevacizumab-treated patients and examination of the impact on the therapeutic effect. <i>Cancer Medicine</i> , 2021, 10, 164-172.	1.3	10
9	Risk Stratification and Management of Arterial Hypertension and Cardiovascular Adverse Events Related to Cancer Treatments: An Oncology Network from Piedmont and Aosta Valley (North-Western) Tj ETQq0 004gBT /Overlock 10	0.4	10
10	Onco-hypertension: Overview of hypertension with anti-cancer agents. <i>Journal of Onco-Nephrology</i> , 2021, 5, 57-69.	0.3	8
11	Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study. <i>BMC Cancer</i> , 2021, 21, 133.	1.1	7
12	Effect of Metabolic Syndrome and Individual Components on Colon Cancer Characteristics and Prognosis. <i>Frontiers in Oncology</i> , 2021, 11, 631257.	1.3	6
13	Etiology and management of hypertension in patients with cancer. <i>Cardio-Oncology</i> , 2021, 7, 14.	0.8	27
14	Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma. <i>Frontiers in Oncology</i> , 2021, 11, 664853.	1.3	44
15	Associations between initiating antihypertensive regimens on stage Iâ€“III colorectal cancer outcomes: A Medicare SEER cohort analysis. <i>Cancer Medicine</i> , 2021, 10, 5347-5357.	1.3	7
16	Peri-radiosurgical administration of bevacizumab improves radiographic response to single and fractionated stereotactic radiosurgery for large brain metastasis. <i>Journal of Neuro-Oncology</i> , 2021, 153, 455-465.	1.4	1
17	Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients. <i>Frontiers in Pharmacology</i> , 2021, 12, 711813.	1.6	9
18	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. <i>European Heart Journal</i> , 2022, 43, 280-299.	1.0	213

#	ARTICLE	IF	CITATIONS
19	The Meta-Analysis of Bevacizumab Combined with Platinum-Based Treatment of Malignant Pleural Effusions by Thoracic Perfusion. <i>Journal of Oncology</i> , 2022, 2022, 1-13.	0.6	5
20	VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications. <i>Current Oncology Reports</i> , 2022, 24, 463-474.	1.8	28
21	Onco-hypertension: An Emerging Specialty. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 477-489.e1.	0.6	11
22	Dual sEH/COX-2 Inhibition Using PTUPBâ€™A Promising Approach to Antiangiogenesis-Induced Nephrotoxicity. <i>Frontiers in Pharmacology</i> , 2021, 12, 744776.	1.6	4
23	Pre-existing hypertension is associated with poor progression-free survival in newly diagnosed multiple myeloma patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, , 1.	1.0	0
24	Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review. <i>Current Cardiology Reviews</i> , 2023, 19, .	0.6	3
25	Advances in Research on VEGF Pathway Inhibitors Related Renal Injury. <i>Advances in Clinical Medicine</i> , 2022, 12, 7462-7472.	0.0	0
27	Cancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies. <i>JACC: CardioOncology</i> , 2023, 5, 159-173.	1.7	4
32	Onco-Hypertension: Anticancer Therapy-Associated Hypertension. , 2024, , 456-465.		0
35	Case report: Successful treatment of a patient undergoing haemodialysis with multifocal hepatocellular carcinoma using atezolizumab and bevacizumab. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1